Last reviewed · How we verify
NCT06719427
qEEG Brain Signature of Depression & Neuromodulation-induced Recovery
Phase 1 trial testing Transcranial Magnetic Stimulation in Major Depressive Diorder in 100 participants. Currently enrolling.
1 January 2027
Quick facts
| Lead sponsor | Sunnybrook Health Sciences Centre |
|---|---|
| Phase | Phase 1 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 100 |
| Start date | 6 January 2025 |
| Primary completion | 1 January 2027 |
| Estimated completion | 1 January 2028 |
| Sites | 2 locations across Canada |
Drugs / interventions tested
- Transcranial Magnetic Stimulation — full drug profile →
Conditions studied
- Major Depressive Diorder — all drugs for Major Depressive Diorder →
Sponsor
Sunnybrook Health Sciences Centre — full company profile →
Who can join
Adults 18 to 80, any sex, with Major Depressive Diorder. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study aims to explore how repetitive transcranial magnetic stimulation (rTMS), a treatment for depression, affects brain function. Depression disrupts the brain's complex network or regions that regulate cognition, emotion, and behavior. rTMS targets these disruptions to restore network function. To measure these effects, researchers will use dry quantitative EEG (qEEG), a new technology that records brain electrical activity quickly (15 minutes compared to 1 hour for traditional EEG) without the need for gel or lengthy electrode setups. This study will evaluate a novel qEEG activity developed by iMediSync (Republic of South Korea) in patients treated with neuromodulation for depression before, during, and up to 12 months after treatment to see if changes in brain activity to identify patterns associated with symptomatic improvement and relapse risk. Findings could help personalize depression treatments by predicting patient outcomes and optimizing care.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06719427
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Transcranial Magnetic Stimulation
Trials testing the same drug.
- NCT07526285 — Personalized Repetitive Transcranial Magnetic Stimulation (PrTMS) for Treatment of Post-Traumatic Stress Disorder (PTSD) · NA · not yet recruiting
- NCT07050862 — rTMS for Tobacco Use in Veterans · NA · not yet recruiting
- NCT07145866 — Varenicline and Accelerated Transcranial Magnetic Stimulation (TMS) for Quitting Nicotine Use (Pilot Study) · Phase 4 · not yet recruiting
- NCT07516028 — Brain Connectivity and Corticospinal Excitability in Response to Moderate Hypoxia · NA · not yet recruiting
- NCT07389694 — Using Transcranial Magnetic Stimulation to Treat Stuttering · NA · recruiting
Other recruiting trials for Major Depressive Diorder
Currently open trials in the same condition.
- NCT07281352 — RCT of Psilocybin-assisted CBT for Depression · Phase 1, PHASE2 · recruiting
- NCT07362511 — Imagery Rescripting in Primary Care · NA · recruiting
- NCT06641726 — Creating a Global Research Database That Connects Genetic Information and Long-term Health Data to Improve Personalized · recruiting
- NCT06728280 — Efficacy and Safety of DTMS in Adolescent Major Depressive Disorder · NA · recruiting
- NCT06616116 — Stress Management with Real-time Bio-signal Biofeedback · NA · recruiting
Other Sunnybrook Health Sciences Centre trials
Trials by the same sponsor.
- NCT07478705 — Early Detection of Metastatic Recurrence Among Patients With Stage II or III Triple Negative Breast Cancer Using Liquid · NA · not yet recruiting
- NCT07376018 — Ketogenic Diet and Neuromodulation in Treatment Resistant Depression · NA · not yet recruiting
- NCT07350278 — Comparing Virtual Reality Simulation to High Fidelity Simulation as an Educational Modality for Electroconvulsive Therap · NA · not yet recruiting
- NCT07191145 — Eary Infusion of Eptinezumab for TreatmEnt of ACute Post-Traumatic Headaches (ELITE-ACT) · Phase 3 · not yet recruiting
- NCT07308587 — Evaluation of Intercostal Neuralgia in Patients With Chest Tube Insertion After Traumatic Rib Fracture · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06719427 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Sunnybrook Health Sciences Centre
- Last refreshed: 3 March 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06719427.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing